Cortexyme, Inc. (CRTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRTX Stock Price Chart Interactive Chart >
CRTX Price/Volume Stats
Current price | $2.40 | 52-week high | $40.66 |
Prev. close | $2.27 | 52-week low | $2.22 |
Day low | $2.23 | Volume | 443,600 |
Day high | $2.43 | Avg. volume | 680,345 |
50-day MA | $3.23 | Dividend yield | N/A |
200-day MA | $10.73 | Market Cap | 72.36M |
Cortexyme, Inc. (CRTX) Company Bio
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.
Latest CRTX News From Around the Web
Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.
Short Sellers Were Right About These 10 StocksIn this article, we discuss the 10 stocks that short sellers were right about. If you want to skip our detailed analysis of these stocks, go directly to Short Sellers Were Right About These 5 Stocks. Short-sellers were the headliners of early 2021. A year later, these short-sellers are once again in the spotlight amid […] |
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 WeeksCortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the FirmOngoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm |
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the FirmLOS ANGELES--(BUSINESS WIRE)---- $CRTX #CRTX--The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm |
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation CRTXNEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
CRTX Price Returns
1-mo | -11.44% |
3-mo | -61.10% |
6-mo | -81.28% |
1-year | -86.59% |
3-year | -83.06% |
5-year | N/A |
YTD | -80.98% |
2021 | 36.29% |
2020 | -50.52% |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...